SBIR/STTR Research Award

TOPIC 369: NOVEL DOSING AND DISPENSING SYSTEM FOR MULTIPARTICULATE CANCER DRUGS

Award identifier bbd5d99ce0ed1a5e3453c9b50041d19f463ebf51796fabda28eccc21f39cde5aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,878,258

Program and phase

SBIR · Phase II

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
HS-DESIGN, INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
MKTMVWX7W5S5
Solicitation number
Not reported
Topic code
NCI

Research abstract

Oncology drugs continue to advance at a rapid pace with many therapies delivered orally as tablets or capsulesSmaller childrenhowevercannot swallow tablets or capsulesFor these drugs to be used in the pediatric population they need to be reformulatedTraditionally this has meant creating a liquid suspensionchewableor rapid dissolve tabletCancer medicationshoweveroften have terrible taste profiles that require large amounts of sugar and flavorants to maskif the taste can be masked at allThe taste issue can lead to longer development times for pediatric formulations and dosing compliance issuesOne potential solution to the taste issue is to formulate the drugs as multiparticulatedrytaste masked microspheresMultiparticulate formulated drugsMPare ideal candidates for giving to children since they can be flavorless do not require liquid reconstitutionand do not require refrigerationThey should be better tolerated by childrenespecially those with sensitivity to flavors as can occur with some cancer therapiesMP drugs also pose a lower risk of toxicity effects from skin contact vsliquid formulationsto patients and caregiversTo dateMP drugs have been delivered in unit dose sprinkle capsules or sachetsWhile those methods might work for singleset dosesthey are not suitable for pediatric cancer drugs which require precision dosing based on weight or size of the childThis lack of delivery system is a major hurdle to the use of MP drugs for pediatric cancerHS DesignHSDis developing theml Sympfinysystem to accurately measure and dose MP drugs in volumes suitable for pediatric cancer treatmentsHSD is taking a platform approachso the system can be tailored for a variety of pediatric cancer drugs

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2017–2019). Reported award amounts total $2,167,701. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.